Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb;40(1):34-48.
doi: 10.1055/s-0039-1697617. Epub 2019 Sep 19.

The Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review

Affiliations
Review

The Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review

Ana Lleo et al. Semin Liver Dis. 2020 Feb.

Abstract

Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease characterized by autoimmune destruction of small to medium size intrahepatic bile ducts. The etiology of PBC remains unknown and pathogenesis features immune-mediated biliary injury, alongside the consequences of chronic cholestasis. PBC is strongly associated with the loss of immune tolerance against mitochondrial antigens and the subsequent presence of an articulated immunologic response that involves both humoral and cellular responses. Both environmental factors and genetic variants increase PBC susceptibility. Biliary epithelial cells have often been considered a passive target of the immune attack in PBC; however, cholangiocyte dedifferentiation, senescence, stress, and deoxyribonucleic acid damage have been recognized to play an active role in the pathogenesis of PBC. This review highlights and discusses the most relevant pathogenetic mechanisms in PBC, focusing on the key factors that lead to the onset of cholestasis and immune activation.

PubMed Disclaimer

Conflict of interest statement

G.M.H. has been a study investigator for PBC and PSC trials within the last five years sponsored by Cymabay, Falk Pharma, FF Pharma, Genfit, Genkyotek, Gilead, GSK, Intercept Pharma, Johnson and Johnson, NGM Bio, Novartis, and Shire. Within the last five years, G.M.H. has consulted ad hoc for Cymabay, Falk Pharma, GSK, Intercept Pharma, and Novartis. M.E.G. has been an investigator to PBC trials sponsored by Arena Pharmaceuticals, Bristol-Myers Squibb, Cymabay Pharmaceuticals, Genentech, and Johnson and Johnson. A.L. has been an investigator to PBC trials sponsored by Intercept Pharma and Lilly. She has consulted for Intercept Pharma, Abbvie, Gilead, and MSD.

LinkOut - more resources